This case demonstrates the potential synergistic efficacy of whole-brain radiotherapy, 125I brachytherapy, and antiangiogenic therapy in advanced epidermal growth factor receptor/anaplastic lymphoma kinase wild-type lung adenocarcinoma, providing a novel salvage strategy for chemotherapy-refractory metastatic disease. The gene discussed is ALK; the disease is metastatic neoplasm.